HRMY(Harmony Biosciences Holdings, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $305.44M | $437.86M | $582.02M | $714.73M | $868.45M |
| 毛利润 | $249.92M | $354.37M | $460.79M | $557.92M | $670.11M |
| 营业利润 | $87.53M | $120.19M | $192.03M | $190.83M | $208.47M |
| 净利润 | $34.60M | $181.47M | $128.85M | $145.49M | $158.69M |
| 经营现金流 | $98.56M | $144.47M | $219.39M | $219.82M | $348.20M |
| 自由现金流 | $98.26M | $144.29M | $219.07M | $218.67M | $347.89M |
| 摊薄每股收益 | $0.58 | $2.97 | $2.13 | $2.51 | $2.71 |